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Summary Background. Early treatment with inhaled corticosteroids may prevent
progression of irreversible obstruction in COPD, especially in patients with bronchial
hyperresponsiveness. We investigated the clinical effects of early introduction of
inhaled steroids in subjects showing early signs and symptoms of COPD without a prior
clinical diagnosis.
Methods. Study subjects were detected in a general population screening and
monitoring program. Those with a moderately accelerated annual FEV1 decline and
persistent respiratory symptoms were invited to participate in a 2-year randomized
controlled trial comparing fluticasone propionate DPI 250 mg b.i.d. with placebo. Pre-
and post-bronchodilator (BD) FEV1, PC20 histamine, functional status (COOP/WONCA
charts) and occurrence of exacerbations were periodically assessed. Subjects
recorded respiratory symptoms. Post-BD FEV1 decline served as the main outcome.
Multivariable repeated measurements analysis techniques were applied.
Results. 48 subjects were randomized (24 fluticasone, 24 placebo). After 3 months,
the post-BD FEV1 had increased with 125ml (SE¼ 68, P ¼ 0:075) and the pre-BD FEV1
with 174ml (SE 90, P ¼ 0:059) in the fluticasone relative to the placebo group. The
subsequent post-BD and pre-BD FEV1 decline were not beneficially modified by
fluticasone treatment. There were no statistically significant differences in
respiratory symptoms, functional status, or exacerbations favoring fluticasone.
Subgroup analysis indicated that the presence of bronchial hyperresponsiveness
modified the initial FEV1 response on fluticasone, but not the subsequent annual FEV1
decline.
Conclusion. Early initiation of inhaled steroid treatment does not seem to affect
the progressive deterioration of lung function or other respiratory health outcomes in
subjects with early signs and symptoms of COPD. In subjects at risk for, or in an early
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stage of COPD, long-term inhaled steroid treatment should not be based on a single
spirometric evaluation after 3 months.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
Bronchial inflammation is the main cause of
bronchial hyperreactivity and symptoms in asth-
ma.1 As a consequence of inflammatory cell
infiltration, goblet cell hyperplasia, basement
membrane thickening and hyperplasia and hyper-
trophy of airway smooth muscle cells, persistent
inflammation of the bronchial wall may cause
irreversible loss of lung function.2 Although its
pathogenesis is less well clarified in chronic
obstructive pulmonary disease (COPD), bronchial
inflammation also seems to play a significant role in
this disease.1
Treatment of asthma is directed at the inflam-
matory process and inhaled steroids are the
cornerstone of asthma management.3 Although in
patients with manifest COPD inhaled steroid treat-
ment may reduce bronchial hyperresponsiveness4
and neutrophilic bronchial inflammation,5–7 the
benefits of maintenance treatment with inhaled
steroids in COPD remain controversial.8 At this
time, recent studies investigating the effectiveness
of inhaled steroids in patients with manifest COPD9–
12 failed to demonstrate significant long-term
effects on the decline of lung function, but there
may be subgroups in which inhaled steroids are
indeed effective in terms of prevention of lung
function deterioration.13,14 Given the controversy
of inhaled steroids in COPD, we hypothesized that
initiation of this anti-inflammatory treatment in
the earliest stages of the disease is critical for its
efficacy in the long term. Because mild bronchial
inflammation and airflow obstruction are not al-
ways accompanied by bronchial symptoms and go
largely unnoticed by patients and primary care
practitioners,15 study participants were selected
from a general population screening program,
which was initiated to detect subjects previously
undiagnosed with COPD or asthma, but with early
signs and symptoms of COPD.
Methods
Study design and recruitment of subjects
A 2-year randomized placebo-controlled double-
blind trial was performed to compare fluticasone
propionate with placebo treatment in subjects with
mild but persistent signs of early COPD detected in
the general population. Study subjects were se-
lected through the two-stage detection strategy of
the DIMCA program (‘‘Detection, Intervention and
Monitoring of COPD and Asthma’’, Fig. 1), which
has been described in detail elsewhere16 but is
summarized here. For the first stage of the
detection strategy, in 10 Dutch general practices
a random sample of all subjects aged 18–75 years
without a prior diagnosis of COPD or asthma was
invited for a screening visit. Screening took place in
the general practices and consisted of spirometric
assessment and a respiratory symptoms question-
naire. Subjects with chronic respiratory symptoms
and signs of persistent airflow obstruction and/or
bronchial hyperresponsiveness were included in the
second stage of the DIMCA program, a 2-year
monitoring phase. During the monitoring, lung
function (including reversibility), bronchial hyper-
responsiveness, occurrence of acute exacerbations
and respiratory symptoms were assessed every 3
months. Based on the screening and monitoring
findings, subjects were categorized into one of five
groups: (1) persistent airflow obstruction (i.e.,
FEV1o80% of the predicted value after bronchodi-
lation); (2) rapid decline in lung function (i.e.,
annual FEV1 decline480ml); (3) persistent respira-
tory signs and symptoms (i.e., annual FEV1 decline
40–80ml and bronchitis symptoms); (4) persistent
mild symptoms and reversible airflow obstruction;
(5) no abnormal respiratory signs or symptoms
during monitoring (‘‘screening false-positives’’).
Group 1–4 subjects were invited to participate in
a series of randomized placebo-controlled trials in
order to assess the efficacy of early initiated
maintenance treatment with inhaled fluticasone.15
There was no evidence of recruitment or selection
bias during the two stages of the detection
program.16 An extensive description of reasons for
non-participation to all different parts of the DIMCA
program has been published elsewhere.17
The current paper reports on the findings in
Group 4, i.e. subjects with persistent respiratory
signs and symptoms of early COPD. Subjects were
included in the trial when, during the 2-year
monitoring, they had reported chronic cough and/
or sputum production for at least three consecutive
months and showed an annual decline in pre-
bronchodilator FEV1 of 40–80ml. Subjects were
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excluded in case of: previous diagnosis of a
pulmonary condition; presence of a co-morbid
condition with reduced life expectancy; intoler-
ance for inhaled b2 agonists; use of b-blocking
agents; inability to use inhalation devices or peak-
flow meters.
In the power calculation we assumed that the
within-subject variation of FEV1 measurement was
100ml. A minimal detectable difference in annual
FEV1 decline of 60ml due to fluticasone treatment
was assumed.18 In an interim analysis of the first
16 subjects who finished the 2-year monitoring
phase, the standard deviation (SD) of the mean
annual FEV1 decline was 66ml.
19 Thus, with a ¼
0:05; 1 b ¼ 0:80 and an anticipated 10% with-
drawal rate, 18 subjects per treatment arm had to
be recruited.
The study was approved by the medical ethics
review board of the University Medical Center
Nijmegen and all trial participants gave written
informed consent.
Treatment arms and rescue medication
Subjects randomized to the active treatment group
received fluticasone propionate (Flixotides) 250mg
b.i.d. by dry powder inhalation (Rotadisks) at each
3-monthly visit to the pulmonary function labora-
tory. Subjects were instructed to return all disks
(full and empty) during the laboratory visits in order
to assess treatment compliance. Individual compli-
ance rates were determined by expressing the
number of puffs consumed (number of dosages
provided minus number of dosages returned) as a
percentage of the amount prescribed during the
trial. Treatment compliance and inhaler technique
were checked half-yearly at the pulmonary function
laboratory. When non-compliance was reported, a
subject was reminded to use the study drug twice
daily. In case of insufficient inhaler technique
additional inhalation instruction was given.
Apart from short-acting (‘‘rescue’’) bronchodila-
tors in case of acute dyspnea, subjects were not
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Figure 1 Flow chart of the initial general population cohort in the DIMCA program,18 and the trial populations derived
from it. This paper reports on the DIMCA 4 trial.
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allowed to use other pulmonary medication. At
each quarterly visit, consumption of rescue inhala-
tions was recorded. At the start of the study, the
participating GPs were reminded of the contents of
the Dutch guidelines for management of asthma
and COPD in general practice, which included a
quit-smoking recommendation. In case of an acute
exacerbation, GPs were advised to prescribe a
10-day course of prednisolone and a broad-spec-
trum antibiotic agent.
Study outcomes and measurements
The primary outcome of the study was the annual
decline of the post-bronchodilator FEV1.
20 Decline
of pre-bronchodilator FEV1, PC20 histamine, ex-
acerbation rate, number of episodes with aggra-
vated symptoms, and use of rescue bronchodilators
were studied as secondary outcomes. At the start
of the trial and after 6, 12, 18 and 24 months, pre-
and post-bronchodilator FEV1 and FVC were as-
sessed by a trained lung function technician in a
certified pulmonary function laboratory using a
Microspiro HI-298 spirometer (Chest Corporation,
Japan).21 Bronchial hyperresponsiveness was mea-
sured half-yearly as the concentration of histamine
provoking a 20% fall in FEV1 (PC20-histamine,
procedure described by Cockcroft et al.22) and
estimated by linear interpolation. Pre- and post-
bronchodilator FEV1 and FVC were also assessed in
the general practices at 3, 6, 9, 15, 18 and 21
months using hand-held turbine spirometers (Micro-
plus, SensorMedics, US). General practice assis-
tants were thoroughly trained in performing
spirometry.23 Following the criteria issued by the
American Thoracic Society, the FEV1 from the
maneuver with the highest sum of FEV1 and FVC
out of three acceptable forced expiratory maneu-
vers was used for analysis.24 In case of 410%
reproducibility (i.e., difference between the high-
est FEV1 value and the mean of all three maneu-
vers) an FEV1 value was excluded from the analysis.
Post-bronchodilator FEV1 was assessed 15
0 after
administration of 800 micrograms salbutamol by
spacer. Measurements were only performed in
exacerbation-free periods and not within 8 h of
bronchodilator use.
Smoking history was assessed at the start of the
trial and expressed as the number of pick-years
smoked. Changes in smoking habit during the trial
were recorded every 3 months. A skin-prick test with
16 allergens (including pollen, house dust mite, fungi,
and pets) was performed. Subjects were considered
to be allergic when the whealsize of X1 allergen
exceeded 2/3 of the histamine control wheal.
Functional status was assessed at the quarterly
general practice visits using the COOP/WONCA
charts.25 This instrument consists of six domains
(‘‘physical fitness’’, ‘‘feelings’’, ‘‘daily activities’’,
‘‘social activities’’, ‘‘changes in health status’’, and
‘‘general health’’) with scores ranging from 1
(‘‘very good’’) to 5 (‘‘very bad’’).
Exacerbations were recorded by the GPs using
standardized report forms. An exacerbation was
defined as at least two positive answers on the
following three items during a consultation: in-
creased cough, wheezing and/or dyspnea; change
in sputum color; use of bronchodilator rescue
medication.26 Consultations with an interval o4
weeks were considered as pertaining to the same
exacerbation.
In order to detect episodes with aggravated
respiratory symptoms, subjects recorded symptom
scores for dyspnea, cough, wheezing and phlegm
for the past week (0: no complaints, 3: complaints
on all days and/or nights during the past week). An
episode was defined as either ‘‘increased cough,
wheezing and/or dyspnea’’, ‘‘change in phlegm
color’’, ‘‘increased use of rescue bronchodilators’’,
and/or ‘‘having a cold’’. When in the next week no
item was reported the episode was considered to
have terminated. Information about serious and
minor adverse events was collected.
Statistical analyses
The SAS statistical software package was used for
analysis. All subjects with at least one follow-up
measurement for the primary outcome (post-
bronchodilator FEV1) were included in an inten-
tion-to-treat analysis. The effects of fluticasone
versus placebo treatment on primary and secondary
outcomes were analyzed using repeated measure-
ments analysis of variance (PROC MIXED),27 in
which subject, treatment, and time effects are
analyzed simultaneously. Short-term responses (0–3
months) and long-term treatment effects (3–24
months) were analyzed in separate models. Base-
line PC20 and number of packyears prior to the
study were included in all models in order to adjust
for their potential confounding effects. Based on
the repeated measurements models, adjusted
estimates of the long-term effect of fluticasone
versus placebo on the decline of post-BD and pre-
BD FEV1 were calculated for the 3–24 month data.
Estimates for longitudinal changes in PC20 hista-
mine were calculated using the full 2-year follow-
up data.
A subgroup analysis was performed to investigate
bronchial hyperresponsiveness (PC20o8 versus
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X8mg=ml) as a potential effect modifier of the
short- and long-term efficacy of fluticasone treat-
ment. This was done by including interaction terms
in the repeated measurements models of the post-
and pre-bronchodilator FEV1. PC20 values were log2
transformed before analysis. Consequently,
changes in PC20 values are expressed as geometric
means and should be interpreted as doubling doses
of histamine. Between-group differences in the
occurrence of acute exacerbations and episodes
with aggravated symptoms were analyzed using
Poisson tests, differences in functional status by
Wilcoxon rank test. Between-group differences
were considered to be statistically significant when
Po0:05:
Results
Study population and drop-outs
Seventy four (74) subjects met the inclusion
criteria (Fig. 1). Of these subjects, 21 declined
the invitation to participate in the trial, the main
reasons being ‘‘general dislike of medication’’,
‘‘general dislike of medical testing’’, and ‘‘lack
of time’’. Five subjects were excluded by the
investigators (two used b-blockers, two moved
away, and one wanted to become pregnant). The
remaining 48 subjects were randomized to receive
either fluticasone or placebo treatment for two
years.
Demographic and clinical characteristics of par-
ticipants and non-participants did not differ (re-
sults not presented). Table 1 shows the baseline
characteristics of the trial participants by treat-
ment group. Fluticasone group subjects had a
higher number of pick-years compared to placebo
group subjects (11.9 [SD 9.5] versus 5.8 [SD 8.4],
respectively, P¼ 0.02). Seven fluticasone and six
placebo-treated subjects showed baseline bron-
chial hyperresponsiveness.
Twelve subjects (25% of the trial population)
dropped out during the 2-year treatment period.
Pharyngeal irritation and aversion to using pulmon-
ary medication in the absence of respiratory
symptoms were the main reasons for drop-out.
Numbers of, and reasons for drop-out were equally
distributed over the fluticasone and placebo
groups. The overall compliance of the use of trial
medication was 72% of the prescribed dose (range
7–102%). Compliance rates were similar in both
treatment groups.
Effects on FEV1 decline and PC20
The course of the post-bronchodilator FEV1, pre-
bronchodilator FEV1, and PC20 in the treatment
groups is depicted in Figs. 2–4. Three months after
randomization, the mean post-bronchodilator FEV1
was 125 (SE 68) ml higher in the fluticasone-treated
subjects compared to the placebo-treated subjects
(P ¼ 0:075; Fig. 2). During the 2-year follow-up the
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Table 1 Baseline characteristics of the study population by treatment group.
Fluticasone propionate
(n¼ 24)
Placebo (n¼ 24)
Age (years) 46 (10) 47 (11)
Male/female 12/12 13/11
Smoker (yes/no) 12/12 8/16
Pick-years 11.9 (9.5) 5.8 (8.4)
FEV1 pre-bronchodilator (I) 3.05 (0.70) 3.17 (0.76)
as % predicted 95 (18) 98 (17)
FEV1 post-bronchodilator (I) 3.16 (0.68) 3.19 (0.79)
as % predicted 98 (15) 99 (18)
FEV1/VC pre-bronchodilator (%) 75 (10) 77 (6)
FEV1 decline during monitor stage 109 (46) 124 (66)
(ml/year)
FEV1 reversibility as % predicted 4.0 (5.1) 3.0 (4.0)
MEF50 as % predicted 65.6 (27.4) 68.5 (24.1)
PC20 histamine
a (mg/ml) 14.2 9.2
Allergy (yes/no/missing) 8/15/1 10/13/1
Symptom score 1.7 (1.5) 1.3 (1.3)
*P¼ 0.02.Values are means (SD) unless stated otherwise.
aGeometric mean.
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estimated annual decline of the post-bronchodila-
tor FEV1 was 93 (SE 30) ml for fluticasone and 14
(SE 17) ml for placebo treatment (P ¼ 0:001). For
the pre-bronchodilator FEV1 the difference be-
tween fluticasone and placebo treatment was 174
(SE 90) ml after 3 months, favoring fluticasone
treatment (P ¼ 0:059; Fig. 3). The annual pre-
bronchodilator FEV1 decline was 85 (SE 32) ml for
fluticasone and 38 (SE 19) ml for placebo
treatment (P ¼ 0:078). At the end of the 2 year
treatment period the difference in post-broncho-
dilator FEV1 was 47 (SE 63) ml in favor of placebo
treatment (P ¼ 0:458), for the pre-bronchodilator
FEV1 the corresponding figure was 60 (SE 70) ml in
favor of fluticasone treatment (P ¼ 0:394). PC20
measurements did not show a significant difference
between fluticasone and placebo treatment at any
point in time (P ¼ 0:980; Fig. 4).
Bronchial hyperresponsiveness as well as pack-
years were confounders in the multivariable models
for both the post- and pre-bronchodilator FEV1
decline. The subgroup analysis on baseline bronchial
hyperresponsiveness showed that, compared to
placebo, fluticasone was significantly more effica-
cious in terms of the short-term (0–3 months) pre-
and post-bronchodilator FEV1 response (Table 2).
However, no modifying effect of bronchial hyperre-
sponsiveness in favor of fluticasone treatment on
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Figure 2 Short-term response and long-term course for the post-bronchodilator FEV1 in the fluticasone (FKF) and
placebo (–~–) groups*. Vertical bars indicate standard errors. (* For reasons of clearness, the general practice
measurements at 6 and 18 months are omitted from the figure (but not from the statistical analysis).)
Figure 3 Short-term response and long-term course for the pre-bronchodilator FEV1 in the fluticasone (FKF) and
placebo (–~–) groups*. Vertical bars indicate standard errors. (* For reasons of clearness, the general practice
measurements at 6 and 18 months are omitted from the figure (but not from the statistical analysis).)
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either the post- or pre-bronchodilator annual FEV1
decline was observed (Table 2).
Effects on exacerbations, respiratory
symptoms and functional status
Six exacerbations in five fluticasone-treated sub-
jects and four exacerbations in three placebo-
treated subjects were reported. In the fluticasone
group, 127 episodes of increased respiratory symp-
toms were reported by 18 subjects, whereas 57
episodes in 17 subjects were observed in the
placebo group (Po0:001). The number and severity
of reported respiratory symptoms did not differ
between the treatment groups, nor did the number
of subjects who used rescue bronchodilators during
the trial: seven subjects in the fluticasone group and
eight subjects in the placebo group, respectively.
The baseline COOP/WONCA chart scores varied
from ‘not impaired’ (1.2, SD 0.6 for social
activities) to ‘slightly impaired’ (2.4, SD 1.2) for
ARTICLE IN PRESS
Figure 4 Course of the PC20 histamine in the fluticasone (FKF) and placebo (–~–) groups. Vertical bars indicate
standard errors.
Table 2 Results of the subgroup analyses on short-term FEV1 response and subsequent annual FEV1 decline with
regard to bronchial hyperresponsiveness.
Short-term response
in ml (SE) 0–3
months
P Annual decline in
ml/year (SE) 3–24
months
P
Post-bronchodilator FEV1
BHRþ
Fluticasone þ 95 (215) 93 (64)
Placebo 200 (125) 0.124 þ 19 (37) 0.032
BHR
Fluticasone þ 56 (84) 92 (33)
Placebo 8 (48) 0.350 27 (18) 0.016
Pre-bronchodilator FEV1
BHRþ
Fluticasone þ 276 (307) 115 (82)
Placebo 401 (178) 0.022 1 (47) 0.093
BHR
Fluticasone 21 (83) 73 (30)
Placebo 14 (48) 0.918 53 (17) 0.403
FEV1: forced expiratory volume in 1 s; BHRþ : bronchial hyperresponsiveness present (PC20p8mg/ml); BHR: no bronchial
hyperresponsiveness present (PC20X8mg/ml).
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general health). The majority of subjects perceived
no changes in COOP/WONCA charts score and
differences between the fluticasone and placebo
groups were never statistically significant (data not
shown).
Adverse events
Four serious adverse events were reported during
the trial: one diagnosis of polymyalgia rheumatica
and three hospitalizations, one for severe head-
ache, one for polyposis nasi, and one for uterus
leiomyoma, none of which could be related to the
trial medication. Fourteen subjects (29% of the trial
population), equally distributed over the flutica-
sone and placebo groups, reported minor adverse
events that could be related to the use of trial
medication: dry mouth; hacking cough after in-
halation of trial medication; sore throat or phar-
yngeal irritation; vomit; hoarseness; and loss of
sense of taste. For five subjects (two fluticasone
and three placebo) minor adverse events were the
reason for dropping-out of the study.
Discussion
This study indicates that early initiation of regular
treatment with fluticasone does have an initial and
short-term effect, but does not seem to alter the
subsequent course of lung function decline in
subjects who are characterized by a moderately
accelerated FEV1 decline and persistent respiratory
symptoms. The short-term effect of fluticasone
appeared to be more pronounced in subjects
with bronchial hyperresponsiveness. No long-term
beneficial effects of fluticasone treatment on
secondary health outcomes (i.e., bronchial hyper-
responsiveness, exacerbations, respiratory symp-
toms, and health status) could be demonstrated.
We considered the post-bronchodilator FEV1 to
be the main outcome parameter in our study.
Contrary to our initial hypothesis but in accordance
with the results of previous long-term studies in
subjects in different stages of COPD,9–12 the post-
bronchodilator FEV1 decline was not decelerated by
inhaled steroid treatment. One could argue that
the value of FEV1 measurements in early or
preclinical stages of COPDFas we would like to
describe our study populationFis doubtful. How-
ever, we observed a slight and statistically sig-
nificant increase of FEV1 in favor of fluticasone
treatment after 3 months of study. A short-term
increase of the FEV1 during treatment with inhaled
steroids, followed by a progressive decline parallel
to placebo has also been reported by other
authors.9,11 Although the FEV1 has been widely
accepted as the gold standard for measuring
bronchial obstruction and thus of the severity of
COPD, the value of FEV1 measurements in very
early stages of COPD is doubtful. The explorative
subgroup analysis suggested that in the subjects
with bronchial hyperresponsiveness, the short-term
FEV1 response due to fluticasone treatment was
significantly larger than in subjects without bron-
chial hyperresponsiveness; this observation corre-
sponds with findings reported for patients with
manifest COPD.4–7 However, the presence (or
absence) of bronchial hyperresponsiveness at base-
line did not seem to influence the efficacy of
fluticasone relative to placebo treatment with
regard to the annual FEV1 decline.
A substantial part of the FEV1 measurements was
performed in the general practices, and our
findings rely heavily on the quality of these
measurements. Repeated instructions of the prac-
tices’ staff resulted in reliable performances, with
an average test reproducibility of 4%.23 Reanalyzing
the data with only the measurements of the lung
function laboratory did not change the main
conclusions.
It has been hypothesized that subjects with mild
obstructive airways disease, whose pathophysiolo-
gic abnormalities are predominantly present in the
small airways, may remain undetected if no flow
rates at low lung volumes are measured.28 Indeed,
at the start of the trial the mid-expiratory flow
(MEF) values were slightly impaired (below 70% of
predicted values in both treatment groups), in-
dicating (mild) obstruction of the peripheral air-
ways. However, when we assessed the course of the
pulmonary function on the MEF25, MEF50, or MEF75
values, no effects of fluticasone in comparison to
placebo on these indices were observed (results not
presented).
In COPD, other characteristics of disease pro-
gression or monitoring of treatment like health
status and exacerbations attract more and more
attention.29 Impaired quality of life is more directly
related to the use of general practitioners’ facil-
ities than respiratory symptoms or a reduced lung
function,30 and impaired quality of life may also be
present in COPD with near normal spirometry.29 In
the current study, no improvement in generic
health status during treatment with fluticasone
was observed, but this is probably due to the
virtually undisturbed health status of the study
subjects at the start of the trial. The rate of acute
exacerbations was very low in both treatment
groups, which may be expected in subjects who
were not previously known by their GP as suffering
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from chronic respiratory disease. Therefore, there
was hardly any room for improvement on this
particular outcome. The salient and statistically
significant difference in the number of episodes
with increased symptomsFone of the secondary
study outcomesFin favor of placebo treatment
was unexpected and we have no explanation for
this observation. We conclude that, in the current
study, we were unable to demonstrate significant
long-term health benefits of early introduction
of inhaled steroid treatment in subjects with
early symptoms and signs of COPD. Primary care
physicians should be careful to base maintenance
treatment with inhaled steroids in subjects at risk
for, or in an early stage of COPD on a single
spirometric evaluation after 3 months. Implemen-
tation of screening or case-finding programs to
detect subjects with early COPD cannot be justified
on the basis of this study.
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